AstraZeneca Reports Results of AZD1222 in Primary Analysis of P-III Trial for the Prevention of COVID-19

 AstraZeneca Reports Results of AZD1222 in Primary Analysis of P-III Trial for the Prevention of COVID-19

Shots:

  • The P-III D8110C00001 study involves assessing AZD1222 vs PBO in 32,449 participants in a ratio (2:1) aged ≥18yrs. across 88 trial centers in the US, Peru and Chile to prevent COVID-19. his primary efficacy analysis included the accrual of 190 symptomatic cases of COVID-19 from total participants
  • The study showed 76% efficacy against symptomatic COVID-19, 85% efficacy in aged ≥65yrs. as its 1EPs and showed 100% efficacy against severe disease and hospitalization in 2EPs. The vaccine was well tolerated with no safety concerns
  • The company will submit EUA to US FDA and also submit the primary analysis for peer-reviewed publication in the coming weeks

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: Mint

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post